BioWorld

May 16, 2011

You're Fired! A Quantitative Analysis of Dissolved Deals

In the first two weeks of this month, pharma firms dissolved four partnerships with biotech companies, continuing a trend that's been troubling the industry. Read More

Is CER the Rx for Personalized Medicine?

Infectious Disease Pipeline Thinner, but Inching Forward

Money Raised Year to Date

Money Raised By Biotech in 2011

Week in Review

Word on the Street

Week in Washington

FDA Approvals in April

Phase I Clinical Trials Update: April 2011

Phase II Clinical Trials Update: April 2011

Phase III Clinical Trials Update: April 2011

American Association for Cancer Research

American College of Cardiology

European Association for the Study of the Liver

Non-U.S. Clinical Trials & Regulatory Actions: April 2011

FDA Submissions, Approvals & Other Actions: April 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...